The Department of Urology is committed to increasing knowledge of urological diseases and through this, improving patient care. The department is actively involved in basic science, translational and clinical research programs.
Our largest research program is in urologic oncology, which focuses on prostate and bladder cancer. In pediatric urology the focus is on understanding stem cells and manipulating cell growth for tissue engineering. In stone disease the focus is on studying the effect that nanobacteria have on stone formation.
The focus of translational research is to bring laboratory investigations into clinical practice. An example of this is recent studies with hAR staining in breast cancer. While immunohistochemistry (IHC)positivity is required for patients with breast cancer to receive herceptin, following our studies, NCI will allow patients with prostate cancer who are either IHC positive or amplified by FISH analysis to receive the drug.
The urological oncology clinical trials are coordinated through the Cancer Center's Clinical Trials Support Unit and cover all aspects of urological cancer. A number of the laparoscopic procedures are being conducted in a clinical trial fashion so researchers can assess utility in urological disease.
Endourology clinical studies are looking at ways to prevent stone formation and understanding the pressure changes that occur during percutaneous stone removal.
The department has a long history of clinical research dealing with a number of aspects of female incontinence. The latest study is looking at the ability of TVT as compared to slings in curing female incontinence.
In pediatric urology, we are evaluating quality of life issues, outcome data and minimally-invasive surgery.